MediPharm Labs Corp.
LABS.TO
TSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -2.61% | 13.35% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.61% | 13.35% | |||
| Cost of Revenue | 5.62% | 31.95% | |||
| Gross Profit | -23.20% | -16.20% | |||
| SG&A Expenses | -36.90% | 58.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 343.26% | 51.25% | |||
| Total Operating Expenses | -12.20% | 43.59% | |||
| Operating Income | 42.34% | -787.94% | |||
| Income Before Tax | 42.92% | -910.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 42.92% | -910.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 42.92% | -910.31% | |||
| EBIT | 42.34% | -787.94% | |||
| EBITDA | 47.60% | -15,019.38% | |||
| EPS Basic | 43.94% | -1,000.00% | |||
| Normalized Basic EPS | 43.90% | -925.00% | |||
| EPS Diluted | 43.94% | -1,000.00% | |||
| Normalized Diluted EPS | 43.90% | -925.00% | |||
| Average Basic Shares Outstanding | 1.30% | 0.05% | |||
| Average Diluted Shares Outstanding | 1.30% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||